New Avenues for Phosphodiesterase Inhibitors in Asthma
Maria Gabriella Matera,1 Josuel Ora,2 Francesco Cavalli,2 Paola Rogliani,2,3 Mario Cazzola3 1Department of Experimental Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy; 2Respiratory Diseases Unit, “Tor Vergata” University Hospital, Rome, Ita...
Saved in:
Main Authors: | Matera MG (Author), Ora J (Author), Cavalli F (Author), Rogliani P (Author), Cazzola M (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2021-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacogenomic Response of Inhaled Corticosteroids for the Treatment of Asthma: Considerations for Therapy
by: Cazzola M, et al.
Published: (2020) -
Differential pharmacology and clinical utility of long-acting bronchodilators in COPD – focus on olodaterol
by: Matera MG, et al.
Published: (2015) -
Roflumilast: Review of Phosphodiesterase-4 Inhibitor as Asthma Therapy
by: Rafina Syfridiana, et al.
Published: (2021) -
Cardiovascular diseases or type 2 diabetes mellitus and chronic airway diseases: mutual pharmacological interferences
by: Mario Cazzola, et al.
Published: (2023) -
The future of inhalation therapy in chronic obstructive pulmonary disease
by: Mario Cazzola, et al.
Published: (2022)